8 June 2016 - Opdivo is the first immuno-oncology therapy for lung cancer in Canada to use the body’s own immune system to fight cancer.

Canada’s national health technology assessment body (CADTH) today made its final, positive recommendation for Opdivo (nivolumab) for the treatment of non-small cell lung cancer (NSCLC), a reflection of the strong clinical evidence that supports the benefits of this immuno-oncology treatment of adult patients with advanced or metastatic NSCLC who progressed on or after chemotherapy.

The CADTH evaluation of the clinical, economic, and patient evidence of Opdivo for the treatment of NSCLC was made under the pan-Canadian Oncology Drug Review process.

For more details, go to: http://www.bmscanada.ca/en/news/release/canada-s-health-technology-assessment-agency-gives-positive-recommendation-for-opdivo-to-treat-non-s